Mar 2, 2026 05:08PM

Feb 26, 2026 04:01PM

Feb 24, 2026 09:05AM

Feb 5, 2026 02:04PM

Feb 5, 2026 02:00PM

Jan 29, 2026 04:00PM

Jan 29, 2026 04:00PM Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™

Jan 15, 2026 04:22AM

Jan 7, 2026 12:41AM

Jan 6, 2026 08:04AM

Jan 6, 2026 08:00AM

Dec 30, 2025 09:57AM

Dec 30, 2025 08:00AM

Dec 30, 2025 08:00AM The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Dec 4, 2025 07:10AM

Dec 4, 2025 07:02AM

Dec 4, 2025 07:00AM

Nov 17, 2025 09:28AM

Nov 6, 2025 04:01PM

Nov 6, 2025 04:00PM

Nov 6, 2025 04:00PM Denali Therapeutics Announces Board and Executive Leadership Updates

Oct 15, 2025 07:25AM

Oct 14, 2025 07:05AM

Oct 13, 2025 04:01PM

Oct 13, 2025 04:01PM

Aug 11, 2025 04:01PM

Jul 7, 2025 10:13AM

Jul 7, 2025 08:03AM FDA accepts Denali Therapeutics' (DNLI) hunter syndrome drug application

Jul 7, 2025 08:00AM

May 6, 2025 04:01PM

Jan 28, 2020 09:23AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All